•Senior leader in Strategic Planning division of agency focused on devising strategies to increase revenues and market share for major pharmaceutical and biotech companies like Janssen, Pfizer, Alexion, Otsuka, Shire, and Boehringer Ingelheim•Lead both account and creative teams in developing overall brand strategy with a focus on market research, product positioning, promotional messaging, launch planning, and life-cycle management•Act as consultant to senior brand directers on all aspects of pharmaceutical marketing including business plan development, market research, forecasting, new product development, life-cycle management, clinical trial planning, KOL relations, and franchise management

•Provided strategic advice and counsel to executives from Forest Laboratories, Schwarz Pharmaceuticals, and UCB on marketing and sales strategies, publication planning, new indication launches, financial forecasting and sales training•Developed and executed market research plan to determine product positioning and brand strategy while creating metrics to track KPIs through series of focus groups, IDIs, KOL interviews, quantitative, and tracking studies•Created business plans for 2 start up companies detailing plans for market research, positioning, branding and advertising, sales and promotion, life-cycle management, and financial planning •Worked with Memory Lane, LLC on developing customer relationship marketing (CRM) programs designed to engender compliance and persistency through patient education for major brands in the pharmaceutical industry

•Product management on several blockbuster brands including Celexa, Lexapro and Namenda. •Responsibilities included advertising, campaign development, public relations, adviser relations, market research, financial forecasting, and project management. •Duties and accomplishments include: Development of launch plans, competitive analyses, budgets, and sales strategies •Implementation of core strategic marketing and promotional programs, including: publication planning, medical education, public relations, KOL development, and professional relations•Accountability for early commercialization efforts for four new indications for Namenda and neramexane